Women whose HER2-positive early breast cancers were treated with Genentech Inc.'s Herceptin (trastuzumab) and chemotherapy after surgery saw greater risk reductions for invasive disease recurrence or death when Perjeta (pertuzumab) was added to treatment, a phase III study found.